Stockscreener 앱 받기
26.05
2.51%
-0.67
시장 영업 전:
27.40
1.35
+5.18%
전일 마감가:
$26.72
열려 있는:
$26.8
하루 거래량:
654.84K
Relative Volume:
0.59
시가총액:
$1.51B
수익:
$11.13M
순이익/손실:
$-114.59M
주가수익비율:
-11.26
EPS:
-2.313
순현금흐름:
$-113.96M
1주 성능:
+0.15%
1개월 성능:
-9.52%
6개월 성능:
+0.12%
1년 성능:
+110.42%
1일 변동 폭
$25.60
$27.07
1주일 범위
$24.65
$27.07
52주 변동 폭
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
26.05 | 1.55B | 11.13M | -114.59M | -113.96M | -2.313 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 개시 | Alliance Global Partners | Buy |
| 2025-06-26 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | Roth Capital | Buy |
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
CAPR Stock Sinks After-Hours: Capricor Launches Legal Fight Over DMD Therapy Rollout Ahead Of FDA Review - Stocktwits
CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits
Capricor Therapeutics eyes FDA approval path for Duchenne cell therapy - MSN
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy - MarketBeat
Capricor Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
Trading Systems Reacting to (CAPR) Volatility - Stock Traders Daily
CAPR Stock Draws Investor Attention After AAN Presentation For DMD Therapy - Stocktwits
CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains - Stocktwits
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval - Stocktwits
Capricor (NASDAQ: CAPR) reports 2026 shareholder meeting vote tallies - Stock Titan
Capricor Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Capricor Therapeutics to Participate in Upcoming Investor Conferences in Miami - Quiver Quantitative
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits
Capricor Therapeutics Boosts FDA Approval Preparation for Deramiocel - HarianBasis.co
Deramiocel Outlook Strengthens Capricor Therapeutics, Inc. (CAPR) as a Small-Cap Stock to Buy - Insider Monkey
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
5 Most Shorted Mid-Cap and Small-Cap Stocks to Buy Now - Insider Monkey
Assessing Capricor Therapeutics (CAPR) Valuation After Recent Share Price Cooling And Phase 3 Progress - Sahm
Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis - Seeking Alpha
Capricor Shares Fall, FDA Call in August Looms - Bez Kabli
US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug - Streetwise Reports
Capricor expands commercial leadership team - The Pharma Letter
What is the latest on Capricor Therapeutics' Deramiocel and its FDA journey - Kavout
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks - BioPharma Dive
How Capricor Therapeutics Inc. (CAPR) Affects Rotational Strategy Timing - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
CAPR Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineNext Quarter Guidance - thelegaladvocate.com
Capricor Therapeutics (CAPR) names CCO Michael Maurer as SEC reporting insider - Stock Titan
Capricor (CAPR) CCO Michael Maurer awarded 80,000 stock options at $29.36 - Stock Titan
NeoVolta (NEOV) Q1 2026 Earnings: EPS Beats Estimates Despite Revenue Absence, Stock Drops 23.64%Earnings Surprise Report - thelegaladvocate.com
Capricor Therapeutics (CAPR) Slips Slightly as Stock Consolidates Near Key ResistanceFloat Adjusted Cap - thelegaladvocate.com
‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win - MSN
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
CAPR Stock Price, Quote & Chart | CAPRICOR THERAPEUTICS INC (NASDAQ:CAPR) - ChartMill
Capricor drops following filing of lawsuit against Nippon Shinyaku - MSN
A Look At Capricor Therapeutics (CAPR) Valuation After Deramiocel Launch Delay And Milestone Cut - Sahm
Tesla Launches Full Self-Driving (Supervised) in China Amid Intensifying EV CompetitionRevenue Report - thelegaladvocate.com
United States Duchenne Muscular Dystrophy Therapeutics Market - openPR.com
How Investors May Respond To Capricor Therapeutics (CAPR) Deramiocel Regulatory Uncertainty After Wider Q1 Loss - Sahm
Capricor Therapeutics says NS Pharma delays could threaten access to Duchenne therapy - MSN
Should you sell your Capricor Therapeutics stock? - Cantech Letter
Capricor’s Earnings Call: Deramiocel Drives High-Stakes Pivot - TipRanks
CAPR stock sinks after-hours: Capricor launches legal fight over DMD therapy rollout ahead of FDA review - MSN
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):